drugset
drugset / Trial / NCT05391776

TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

NCT05391776 ↗

Phase 1 Unknown 32 enrolled HJB (Hangzhou) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a placebo-controlled, single-ascending dose, multicenter Phase I clinical study to evaluate the safety, tolerability, PK and PD characteristics of a single intravenous infusion of TST002 in subjects with reduced bone mineral density.

Timeline

Start
2022-04-28
Primary completion
2023-04-28
Completion
2023-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TST002 Unknown 200 mg Intravenous
Subject TST002 Unknown 400 mg Intravenous
Subject TST002 Unknown 800 mg Intravenous
Subject TST002 Unknown 1200 mg Intravenous

Indications

osteoporosis